[A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases].
Clinical approbation of human recombinant yeast human interleukin-2 (rIL-2) was carried out in 10 patients with III-IV stages of tumor that have undergone 65 intravenous drop by drop infusions of the drug as a course of 5-11 injections in the dosage of 1-8 mln/un. The drug toxicity was shown in 4 mln and especially, in 8 mln/un dose administration. That's why the dose of 1-2 mln/un is recommended. This dose was not followed by any serious complications, and the number of slightly complicated cases was significantly decreased as compared to similar rIL-2 drug made by the "Cetus Corporation" firm. Immunostimulating effect of yeast rIL-2 was found which appeared to be able to reach it's maximum by 3-4 administrations, with it's following disappearance or inversion, which may cause immunosuppression.
M V
MV
Grinev
Iu N
IuN
Tsibin
M N
MN
Tarelkina
M I
MI
Gromov
D M
DM
Shirokov
L P
LP
Pivovarova
G M
GM
Frolov
N K
NK
Razumova
T I
TI
Masiianskaia
O B
OB
Ariskina
D000328:Adult; D000917:Antibody Formation; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013350:Subclavian Vein; D013997:Time Factors
D007376:Interleukin-2; D011994:Recombinant Proteins
Pervyĭ opyt ispol'zovaniia chelovecheskogo rekombinantnogo interleĭkina (rIL-2) u patsientov s opukholevymi zabolevaniiami.